7th Jun 2022 21:19
Roquefort Therapeutics PLC - London-based biotechnology company - During the first half of 2022, the company says it has focused on progressing its collaboration with Murdoch University in Australia and reviewing its portfolio. Chair Stephen West says it has been a "very active start" to the year with "significant progress" made.
"The collaboration with Murdoch University is yielding encouraging results with the company's lead oligonucleotide drug candidates. In addition, we are delighted that the review of the wider portfolio acquired with Lyramid has resulted in the conclusion that two of the antibody programs have high commercial potential and we will therefore be accelerating development of those as we aim to be the first to market with an anti-Midkine oncology antibody," West continues.
Current stock price: 8.07 pence
12-month change: up 11%
By Heather Rydings; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Roquefort Thera